PRS48 Estimation of Generic Utilities in Spanish Chronic Obstructive Pulmonary Disease Patients  by Miravitlles, M. et al.
A374  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
Objectives: Adherence and health-related quality of life (HRQoL) are two impor-
tant indicators in determining success of drug treatments. Although medication 
adherence and HRQoL have been studied intensively, less is known about the asso-
ciation of these factors. This research aims to undertake a systematic review of the 
published literature on the relationship of medication adherence and HRQoL in 
patients with chronic obstructive pulmonary disease (COPD). No comprehensive 
review has been published in this topic so far. MethOds: Peer-reviewed English-
language articles that examined the relationship between adherence/compliance/
persistence to medication and HRQoL in COPD were identified through database 
(Medline, EMBASE) searches. Reports until April 2013 were screened. Papers related 
to oxygen therapy were excluded. Results: Of the 243 papers reviewed, eight stud-
ies met the inclusion criteria and were analyzed in our systematic review. Evidence 
suggests that relationship between medication adherence and HRQoL is dual. Non-
adherence does not have a clear negative impact on HRQoL. Adherence to medica-
tion may affect HRQoL due to more factors, such as effectiveness/efficacy and side 
effects of the medication, daily life limitation and social stigmatization caused by 
the therapy. Effect of non-adherence on HRQoL can be derived from the resultant 
of these factors. Nevertheless, HRQoL may also influence patients’ drug use; poor 
or good HRQoL may trigger non-adherence. Relationship between adherence and 
HRQoL may differ depend on the duration of the previous therapy (as therapy in 
newly diagnosed COPD patients may improve HRQoL more than in patients treated 
previously for longer durations) and on the study design (cross-sectional versus 
longitudinal follow-up study) as well. cOnclusiOns: Association of medication 
adherence and HRQoL is multiple. Results from previous studies are limited. Further 
scientific evaluations are needed to better understand the dynamics between these 
factors. Such information would be critically important and needs to be considered 
when integrating adherence into health-economic evaluations.
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Objectives: Chronic obstructive pulmonary disease (COPD) is a major public health 
problem and one of the leading causes of chronic morbidity and mortality worldwide. 
This study aims at determining generic utilities for Spanish COPD patients stratified by 
international guidelines GOLD 2006 (airflow limitation) and GOLD 2013 (airflow limita-
tion, exacerbation history and symptoms), and Spanish guidelines GesEPOC (clinical 
phenotypes). MethOds: Multicentre, observational, cross-sectional study, carried out 
in 15 Pulmonology Spanish public services, including patients aged 40+, diagnosed with 
COPD, who have not experienced an exacerbation in the previous 2 months and receiv-
ing pharmacological treatment for COPD. Utilities were derived from EQ-5D-3L scores. 
Medians, means and standard deviations (SD) were computed for groups of patients 
based on GOLD 2006, GOLD 2013 and GesEPOC classifications. Differences in median 
utilities between groups were assessed by means of Kruskal-Wallis tests. Post-hoc pair-
wise comparisons were based on Wilcoxon tests (Bonferroni-adjusted). Results: A 
total of 346 patients were included in the analysis. Statistically significant median dif-
ferences in utilities by groups of patients were found. GOLD 2006: moderate (n= 135, 
median= 0.87, mean= 0.81, SD= 0.22); severe (n= 145, median= 0.80, mean= 0.71, SD= 0.29); 
very severe (n= 66, median= 0.67, mean= 0.57, SD= 0.35); (p< 0.001). All pair-wise compari-
sons were statistically significant (p< 0.001). GOLD 2013: group A (n= 28, median= 0.98, 
mean= 0.94, SD= 0.06); group B (n= 66, median= 0.87, mean= 0.80, SD= 0.22); group C (n= 30, 
median= 0.98, mean= 0.87, SD= 0.24); group D (n= 222, median= 0.74, mean= 0.66, SD= 0.30); 
(p< 0.001). All pair-wise comparisons were statistically significant (p< 0.002), except-
ing groups A and C comparison. GesEPOC: (A) non-exacerbator (n= 215, median= 0.84, 
mean= 0.78, SD= 0.23); (B) overlap COPD-asthma (n= 21, median= 0.80, mean= 0.80, 
SD= 0.19); (C) exacerbator with emphysema (n= 46, median= 0.74, mean= 0.59, SD= 0.40); 
(D) exacerbator with chronic bronchitis (n= 64, median= 0.74, mean= 0.62, SD= 0.33); 
(p< 0.001). Pair-wise comparisons between phenotypes A and C (p< 0.002) and pheno-
types A and D (p< 0.001) were statistically significant. cOnclusiOns: Generic utilities 
are associated with airflow limitation, exacerbation history, symptoms and clinical 
phenotypes in a sample of Spanish COPD patients.
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Objectives: 1) To identify COPD products approved with a Patient-Reported Outcome 
(PRO) labeling claim in Europe and the USA, and 2) to list the differences found in 
Europe vs. the USA in terms of products and labeling. MethOds: The search was 
performed on the FDA- and EMA-approved medicinal product labels and medical 
reviews/scientific discussions (from January 1995 - February 2013 inclusive). Results: 
A total of 25 COPD products were retrieved: 11 were approved by the EMA and 14 
by the FDA. Only three INN were approved by both agencies (aclidinium bromide, 
indacaterol, and roflumilast), representing 11 products (EMA, n= 8; FDA, n= 3). Out of 
the 25 products approved, 15 have a PRO claim (EMA, n= 8; FDA, n= 7). When focusing 
on the INN approved by both agencies, the review showed that the FDA and the EMA 
agreed on the granting of a PRO claim (i.e., “yes” for aclidinium bromide and inda-
caterol, and “no” for roflumilast). The FDA and the EMA reviewed the same clinical 
studies. However, the labeling text differs between the agencies. The FDA label of acli-
dinium bromide does not provide any mention of results measured by the St. George’s 
Respiratory Questionnaire (SGRQ) and the Transition Dyspnoea Index (TDI), while the 
EMA label does. As for indacaterol, the FDA label does not mention any TDI results, 
while the EMA label does. Reasons for these discrepancies are found in the FDA medi-
cal reviews. The TDI has been assessed as inadequate for use as a CT endpoint. As for 
the SGRQ, the results met the threshold of clinically meaningful improvement in only 
Both groups were similar at baseline. Drop out was 28.8%. Intention to treat analysis. 
Adherence increased significantly in IG (p= 0.046), NNT= 6.37 (CI95%,3.25-142.8). Factors 
related to adherence: intervention (OR= 1.88, CI95%,1.01-3.52), number of exacerbation 
(OR= 0.66,CI95%,0.48-0.91), number of visits to health centre (OR= 0.93,CI95%,0.87-1.00), 
severity (OR= 0.677,CI95%,0.43-1.04), number of devices (OR= 2.4,CI95%,1.09-5.30), SGRQ-
Activity scale (OR= 0.978,CI95%,0.95-1.00), SGRQ-Impact scale (OR= 1.03,CI95%,1.00-1.06), 
inhaled-beta2-adrenérgic (OR= 0.16, CI95%,0.059-0.43), xanthine (OR= 0.199, CI95%,0.05-
0.77). Rho coefficient= 6.07x10-6 (p= 0.498). cOnclusiOns: The more adherent patient 
was that who showed a lower number of visits to health centre, exacerbations, number 
of devices, level of severity, and impact on daily activities but with higher disease impact. 
The beta-2-adrenergic and xanthine treatment are associated with no adherence.
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Objectives: To test the inhaler use in COPD patients. Frequent mistakes. MethOds: 
Design: Cross-sectional study at the beginning of a Multicenter patients’ prefer-
ence trial (ISRCTN15106246) Patients: 465 COPD patients from 9 health care centres, 
with inhaled treatment, written consent. Non-probabilistic consecutive sampling. 
Variables: inhaler devices, performance of correct inhalation technique, type of mis-
takes. Age, sex, Inhalatory pick flow, COPD severity stage, prescribed medication. 
Basal dyspnea index (BDI). Statistical analysis: Mean, frequency. 95% confidence inter-
val. Results: Predominance of males (91.4%), mean age 69.8 years (CI95%,69.00-70.59); 
FEV1(mean)= 55.91%(IC95:53.62-58.2), mixed respiratory pattern (65.9%). Severity stage: 
15.7% mild, 44.1% Moderate, 40.3% Severe. Pharmacological treatment: inhaled-beta2-
adrenergic (88.8%); inhaled-corticosteroids (76.7%); inhaled-anticholinergic (70.7%); 
mucolitycs (19.4%); xanthine (7.3%); oral-corticosteroids (1.3%). BDI: grade 2. Inhalation 
technique: 84.9% had received instruction about inhalation techniques (48.6% from neu-
mologist, 42.1% from general practitioner). The instruction was an explanation without 
device (59.6%). 67.3% of patients used Handihaler, 54.8% Accuhaler, 31.8% Turbuhaler, 
26.9% pressurised metered dose inhaler (pMDI). The 91.3% of patients performed an 
incorrect inhalation technique with handihaler, 89.5% with Turbuhaler, 85.6% with 
Accuhaler and 91.7% with pMDI. The most common mistakes in all devices were related 
to the action consist on: emptying or almost emptying the lungs before activating the 
spray (79.8%) and holding breath for at least 8-10 seconds or for as long as possible 
when inhalation is complete (69.5%). The most common mistakes per device were 
related to: repeating the inhalation with Handihaler (10%), Loading the dispenser cor-
rectly in Accuhaler (8.2%) or Turbuhaler (16.6%) and hand-breath coordination in pMDI 
(52.8%). cOnclusiOns: A high percentage of patients with COPD performed an incor-
rect inhalation technique although they had been received instruction about this. The 
most common mistakes are more related to the patient’s attitude than to the type of 
device.
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Objectives: to test the efficacy of two educational interventions to improve the 
inhalation techniques in patients with COPD and the influence of patient’ prefer-
ence. MethOds: Design: Multicenter patients’ preference trial or comprehensive 
cohort design ISRCTN15106246. Patients: 465 COPD patients (to detect a difference 
between groups of 25%, 80% statistical power, 95% confidence level, 40% expected 
losses), with inhaled treatment, written consent. Non-probabilistic consecutive sam-
pling. Allocation: Patients without strong preferences for a treatment are randomised: 
RCT group (block randomization), and those with strong preferences are given their 
choice: PPS group. Variables: Primary outcomes: Performance of correct inhalation tech-
nique. Secondary outcomes: Pick flow, dyspnea (Baseline dyspnea index), Functional 
status (forced spirometry). Interventions: Intervention-A: Written information. A leaf-
let with the correct inhalation technique for the main inhaler devices used in our 
area. Intervention-B: Intervention-A + individual training (by instructors). Follow-up: 3 
month, visits: baseline, 1 month, 3 month. Statiscal analysis: Mean, frequency, 95% 
confidence interval at baseline. Number Needed to Treat for a benefit (NNT) was cal-
culated. Intention to treat analysis. Results: Predominance of males (91.4%), mean 
age 69.8 years (CI95%, 69.00-70.59); FEV1(mean)= 55.91% (IC95%, 53.62-58.2), mixed 
respiratory pattern (65.9%). Severity stage: 15.7% mild, 44.1% Moderate, 40.3% Severe. 
Pharmacological treatment: inhaled-beta2-adrenergic (88.8%); inhaled-corticosteroids 
(76.7%); inhaled-anticholinergic (70.7%); mucolitycs (19.4%); xanthine (7.3%); oral-corti-
costeroids (1.3%). BDI: grade 2. Primary outcome: better inhalation technique (p= 0.002) 
in the PPS group, NNT= 7.4 (IC95%, 4.52-20).Among the RCT cohorts: there was no differ-
ence between control and intervention A and there were statistically significative dif-
ferences between intervention B versus control (p< 0.0001), NNT= 2.44 (IC95%, 1.87-3.5) 
and versus intervention A, NNT= 2.85 (IC95%, 2.08-4.56). In the PPS cohorts: there was a 
difference (p< 0.0001) between intervention B versus intervention A, NNT= 2.33 (IC95%, 
1.5-3.2). cOnclusiOns: The performance of a correct inhalation Technique improves 
with monitor training. The patients’ preferences enhance the efficacy of intervention.
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